What it's for (Indications)
- Lincomycin is an antibiotic belonging to the lincosamide class, primarily indicated for the treatment of serious infections caused by susceptible strains of Gram-positive organisms.
- Its use is generally reserved for situations where penicillin or other less toxic antibiotics are contraindicated, for instance, in patients with a documented history of penicillin allergy, or when the causative organism has demonstrated resistance to other conventional first-line agents.
- Comprehensive susceptibility testing of the pathogen is crucial before initiating therapy to ensure efficacy.
- Specific clinical indications for lincomycin include: * **Serious Skin and Soft Tissue Infections:** This encompasses conditions such as cellulitis, furunculosis, impetigo, carbuncles, and abscesses, particularly when these are caused by susceptible strains of *Staphylococcus aureus* and *Streptococcus pyogenes*.
- Lincomycin's favorable tissue penetration makes it effective in these deep-seated infections.
- * **Bone and Joint Infections:** Including osteomyelitis and septic arthritis, which are frequently caused by *Staphylococcus aureus*.
- Lincomycin exhibits good bone penetration and achieves therapeutic concentrations in bone tissue, making it a valuable option for these challenging infections.
- * **Respiratory Tract Infections:** For serious bacterial pneumonia, bronchitis, and tonsillitis caused by susceptible streptococci and staphylococci, especially when alternative treatments are not suitable or effective, or in patients with hypersensitivity to beta-lactam antibiotics.
- * **Septicemia:** In cases of bloodstream infections caused by susceptible Gram-positive organisms, lincomycin can be used as part of a treatment regimen.
- * **Other Infections:** Such as otitis media and scarlet fever, where conventional therapies are either ineffective or contraindicated.
- The decision to employ lincomycin should always involve a careful risk-benefit assessment, considering its spectrum of activity and potential adverse effects, notably the risk of pseudomembranous colitis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Lincomycin should be discontinued immediately if significant diarrhea occurs. For intramuscular administration in adults with serious infections, the dose is 600 mg (2 mL) every 24 hours; for more severe infections, 600 mg (2 mL) every 12 hours or more frequently. For pediatric patients over 1 month of age with serious infections, the intramuscular dose is 10 mg/kg (5 mg/lb) every 24 hours; for more severe infections, 10 mg/kg (5 mg/lb) every 12 hours or more frequently. For intravenous administration in adults, the dose is determined by infection severity: serious infections typically require 600 mg (2 mL) to 1 gram every 8 to 12 hours. For more severe infections, these doses may be increased, with daily intravenous doses of up to 8 grams used in life-threatening situations. Intravenous doses require appropriate dilution before administration. |
Safety & Warnings
Common Side Effects
- Common gastrointestinal side effects include persistent diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort, and anal pruritus.
- Severe gastrointestinal effects include colitis (inflammation of the colon), pseudomembranous colitis, and Clostridioides difficile colitis, which may necessitate immediate discontinuation.
- Dermatological reactions can include rash, urticaria, pruritus, and more severe conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, bullous dermatitis, exfoliative dermatitis, and erythema multiforme.
- Hematologic disorders like pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, and thrombocytopenic purpura have been reported.
- Immune system disorders may include anaphylactic reactions, angioedema, and serum sickness.
- Hepatic effects include jaundice, abnormal liver function tests, and increased transaminases.
- Renal impairment and vaginal infections have also been observed.
Serious Warnings
- Black Box Warning: Clostridioides difficile-associated diarrhea (CDAD) has been reported with lincomycin, ranging from mild diarrhea to fatal colitis. Lincomycin alters the normal colonic flora, leading to C. difficile overgrowth. Due to the risk of severe, potentially fatal colitis, lincomycin should be reserved for serious infections when less toxic antimicrobial agents are not suitable.
- Lincomycin therapy is associated with severe colitis, including pseudomembranous colitis and Clostridioides difficile-associated diarrhea (CDAD), which can range from mild to fatal.
- If significant diarrhea occurs, the medication should be discontinued immediately.
- There is no definitive data regarding the use of lincomycin in pregnancy; therefore, caution is advised, and healthcare provider consultation is recommended.
- Precautions are necessary in patients with hepatic (liver), renal (kidney), endocrine, or metabolic disorders.
- Severe hypersensitivity reactions such as anaphylaxis, angioedema, and serum sickness can occur.
- Serious dermatological reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, bullous dermatitis, exfoliative dermatitis, and erythema multiforme, have been reported.
How it Works (Mechanism of Action)
Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome, predominantly acting as bacteriostatic in vitro.